\addvspace {10\p@ }
\addvspace {10\p@ }
\contentsline {figure}{\numberline {2.1}{\ignorespaces BDS report showing pipelineâ€™s task execution timeline}}{73}
\contentsline {figure}{\numberline {2.2}{\ignorespaces Execution example \texttt {pipeline.bds}}}{75}
\contentsline {figure}{\numberline {2.3}{\ignorespaces Whole-genome sequencing analysis pipeline's flow chart}}{76}
\contentsline {figure}{\numberline {2.4}{\ignorespaces Architecture independence example}}{77}
\contentsline {figure}{\numberline {2.5}{\ignorespaces Scaling dataset sized by a factor of \nobreakspace {}1000}}{78}
\addvspace {10\p@ }
\contentsline {figure}{\numberline {3.1}{\ignorespaces Output of SnpEff.}}{82}
\contentsline {figure}{\numberline {3.2}{\ignorespaces Detailed effect list from SnpEff}}{84}
\contentsline {figure}{\numberline {3.3}{\ignorespaces Information provided by SnpEff in tab separated output format (TXT)}}{86}
\contentsline {figure}{\numberline {3.4}{\ignorespaces Information provided by SnpEff in variant call format (VCF)}}{88}
\contentsline {figure}{\numberline {3.5}{\ignorespaces Classification of SNPs in $w^{1118} ; iso-2; iso-3$}}{89}
\contentsline {figure}{\numberline {3.6}{\ignorespaces 60 Genes with start-gaineded SNPs with ATGs}}{90}
\contentsline {figure}{\numberline {3.7}{\ignorespaces Genes with start-gained SNP GO categories in $w^{1118} ; iso-2; iso-3$}}{91}
\contentsline {figure}{\numberline {3.8}{\ignorespaces Analysis of Eip63E start-gained SNP in $w^{1118} ; iso-2; iso-3$}}{92}
\contentsline {figure}{\numberline {3.9}{\ignorespaces Stop gained and stop lost in $w^{1118} ; iso-2; iso-3$}}{93}
\contentsline {figure}{\numberline {3.10}{\ignorespaces Oc/Otd has two stop-gained SNPs in $w^{1118} ; iso-2; iso-3$}}{95}
\contentsline {figure}{\numberline {3.11}{\ignorespaces CG34326 has one stop-gained SNP in $w^{1118} ; iso-2; iso-3$ in the non-conserved C-terminal region.}}{97}
\contentsline {figure}{\numberline {3.12}{\ignorespaces Nonsynonymous to synonymous ratios along the chromosome arms in $w^{1118} ; iso-2; iso-3$}}{99}
\contentsline {figure}{\numberline {3.13}{\ignorespaces CG13958 has a stop lost SNP in $w^{1118} ; iso-2; iso-3$}}{101}
\addvspace {10\p@ }
\contentsline {figure}{\numberline {4.1}{\ignorespaces Analysis pipeline schematic}}{108}
\contentsline {figure}{\numberline {4.2}{\ignorespaces Histogram of log-likelihood values of pairs of amino acids in contact vs not in contact (within protein).}}{117}
\contentsline {figure}{\numberline {4.3}{\ignorespaces Classifier's receiver operator curve (ROC)}}{118}
\contentsline {figure}{\numberline {4.4}{\ignorespaces Histogram of log-likelihood values of pairs of amino acids in contact vs not in contact (co-crystallized proteins)}}{120}
\contentsline {figure}{\numberline {4.5}{\ignorespaces Example of amino acid interaction}}{121}
\contentsline {figure}{\numberline {4.6}{\ignorespaces Results from epistatic GWAS analysis of type II diabetes sequencing data}}{123}
\contentsline {figure}{\numberline {4.7}{\ignorespaces Power calculation using a pure two-loci epistatic model}}{125}
\contentsline {figure}{\numberline {4.8}{\ignorespaces Distribution of $\ell _C$ for interacting genes and non-interacting genes}}{131}
\contentsline {figure}{\numberline {4.9}{\ignorespaces Distribution of $\ell _C$ across different clinical categories from ClinVar database}}{132}
\addvspace {10\p@ }
